About the Company
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TOCA News
Tocagen plummets on phase 3 data for glioma therapy
A phase 3 trial of Tocagen’s therapy for high-grade glioma (HGG) – a form of brain cancer – failed to show an improvement in overall survival, sending the biotech’s shares into freefall.
Forte Biosciences Inc (FBRX)
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune ...
Biotech IPO market heats up as BioHaven's debut impresses
Tocagen raised $85 million at the start of the second quarter, and Ionis Pharmaceuticals’ lipid disorder subsidiary Akcea, is among the group of companies aiming to go public soon. The slow ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Regionals 2024
Inc. Regionals honors the fastest-growing privately held companies by region over a two-year period. These are emerging companies. Research shows these firms also tend to be the biggest job ...
Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant
The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly ...
Loading the latest forecasts...